OTCMKTS:WUXIF WuXi AppTec (WUXIF) Stock Price, News & Analysis → Jeff Bezos Just Humiliated Elon Musk (From InvestorPlace) (Ad) Free WUXIF Stock Alerts $4.35 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$4.35▼$4.3550-Day Range$4.35▼$6.8452-Week Range$4.35▼$12.69VolumeN/AAverage Volume758 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get WuXi AppTec alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About WuXi AppTec Stock (OTCMKTS:WUXIF)WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.Read More WUXIF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WUXIF Stock News HeadlinesApril 30, 2024 | markets.businessinsider.comHere's what to expect from WuXi AppTec's earnings reportApril 29, 2024 | finance.yahoo.comWuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable OperationsMay 5, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.April 26, 2024 | americanbankingnews.comWuXi AppTec Co., Ltd. (OTCMKTS:WUXIF) Short Interest UpdateApril 25, 2024 | ft.comBristol Myers Squibb drafts contingency plans for US restrictions on Chinese pharmaApril 17, 2024 | forbes.comInnovationRx: Legislation Could Prevent Pharma Companies From Working With Chinese ContractorsApril 15, 2024 | msn.comResearch for Sale: How Chinese Money Flows to American UniversitiesMarch 28, 2024 | reuters.comExclusive: China's WuXi AppTec shared US client's data with Beijing, US intelligence officials told senatorsMay 5, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.March 25, 2024 | msn.comChina's WuXi AppTec In Crosshairs of US Draft Biosecurity BillMarch 19, 2024 | marketwatch.comWuXi AppTec's Shares Fall After Downbeat GuidanceMarch 19, 2024 | ft.comWuXi AppTec lobbies against US bill that aims to restrict Chinese pharma groupsMarch 18, 2024 | msn.comWuXi AppTec’s Net Profit Jumps, Reiterates It Doesn’t Pose Security ThreatMarch 18, 2024 | finance.yahoo.comWuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First TimeMarch 15, 2024 | finance.yahoo.comBIO Backflips on US Bill Limiting China Ties as WuXi ExitsMarch 14, 2024 | msn.comWuXi Shares Fall as Washington Lobbying Group Cuts TiesMarch 8, 2024 | uk.finance.yahoo.comTime to 'cut off' US outbound investment in China biotech firms like BGI Group and Wuxi AppTec: House panelMarch 6, 2024 | yahoo.comWuXi AppTec, WuXi Bio Tumble After US Panel Advances Ban BillMarch 6, 2024 | reuters.comUS Senate committee takes up bill targeting China's BGI, WuXi ApptecMarch 6, 2024 | reuters.comUS Senate committee takes up bill targeting China's BGI, WuXi ApptecMarch 4, 2024 | msn.comWuxi Companies’ Shares Rise on Receding Worries About Potential U.S. SanctionsFebruary 26, 2024 | news.yahoo.comUS Senate committee sets hearing on China's WuXi AppTec, BGI billFebruary 21, 2024 | msn.comWuXi ATU gains approval for Amtagvi manufacturing at US siteFebruary 20, 2024 | finanznachrichten.deWuXi AppTec: WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI (lifileucel) for Advanced MelanomaFebruary 20, 2024 | finance.yahoo.comWuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced MelanomaFebruary 18, 2024 | reuters.comChina's WuXi AppTec says it poses no national security risks to USFebruary 16, 2024 | msn.comUS lawmakers urge administration to take action against WuxiSee More Headlines Receive WUXIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for WuXi AppTec and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolOTCMKTS:WUXIF CUSIPN/A CIKN/A Webwww.wuxiapptec.com Phone86-21-5046-1111FaxN/AEmployees41,116Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Ge Li Ph.D. (Age 57)Co-Founder, Chairman, President & CEO Dr. Minzhang Chen Ph.D. (Age 55)Co-CEO & Executive Director Dr. Qing Yang Ph.D. (Age 55)Co-CEO & Executive Director Dr. Edward Hu M.B.A. (Age 62)Vice Chairman of the Board & Global Chief Investment Officer Ms. Ming Shi (Age 50)Senior VP & CFO Mr. Zhaohui Zhang (Age 55)COO of China, VP & Executive Director Mr. Yuanzhou Zhang (Age 36)Joint Company Secretary Mr. Ruijia TangIR DirectorDr. Howard Wu J.D.Senior VP, General Counsel & Global Head of Human ResourcesDr. Jingchao Dong Ph.D.Senior VP & Head of RCSMore ExecutivesKey CompetitorsANGLEOTCMKTS:ANPCYbioAffinity TechnologiesNASDAQ:BIAFWEpigenomicsOTCMKTS:EPGNYEternity HealthcareOTCMKTS:ETAHIntegral DiagnosticsOTCMKTS:ITGDFView All Competitors WUXIF Stock Analysis - Frequently Asked Questions How have WUXIF shares performed in 2024? WuXi AppTec's stock was trading at $9.9301 at the start of the year. Since then, WUXIF stock has decreased by 56.2% and is now trading at $4.3501. View the best growth stocks for 2024 here. Are investors shorting WuXi AppTec? WuXi AppTec saw a decrease in short interest in April. As of April 15th, there was short interest totaling 273,300 shares, a decrease of 70.1% from the March 31st total of 913,600 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 2,733.0 days. View WuXi AppTec's Short Interest. What ETFs hold WuXi AppTec's stock? ETFs with the largest weight of WuXi AppTec (OTCMKTS:WUXIF) stock in their portfolio include First Trust Indxx Medical Devices ETF (MDEV).KraneShares MSCI All China Health Care Index ETF (KURE). How do I buy shares of WuXi AppTec? Shares of WUXIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:WUXIF) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding WuXi AppTec Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
